Janus

Blüm Subsidiary Unrivaled Files Suit Against Bernard Steimann, Dan Troup, and Troup Construction for Theft

Retrieved on: 
Wednesday, March 6, 2024
Janus, Complaint, OTCQB, Social media, Culture, Cannabis

The complaint details Unrivaled’s reputational concerns about continuing to be associated with People’s California, LLC (“People’s California”) and its founders reading in part, “Unrivaled management has received inquiries questioning its association with the People’s brand.

Key Points: 
  • The complaint details Unrivaled’s reputational concerns about continuing to be associated with People’s California, LLC (“People’s California”) and its founders reading in part, “Unrivaled management has received inquiries questioning its association with the People’s brand.
  • Unrivaled is aware that People’s California released a social media video depicting People’s California’s founder and majority owner, Bernard Steimann destroying a field of cannabis plants using a People’s-branded off-road truck.
  • New Patriot is an affiliate entity of People’s California originally incorporated by Mr. Steimann and owned at least in part by Jay Yadon.
  • In other matters, Mr. Colby is counsel to Medalist Diversified REIT, Inc.

People’s First Choice, LLC (“Blüm Santa Ana”) Granted Temporary Restraining Order Against New Patriot Holdings, Inc.

Retrieved on: 
Friday, March 1, 2024
Janus, OTCQB, Hearing, BLMH, JAMS

Mr. Yadon is also a principal of People’s California, LLC, an entity involved in separate litigation with Unrivaled Brands, Inc., a wholly-owned subsidiary of Blüm.

Key Points: 
  • Mr. Yadon is also a principal of People’s California, LLC, an entity involved in separate litigation with Unrivaled Brands, Inc., a wholly-owned subsidiary of Blüm.
  • The matter involved parking spaces used by Blüm Santa Ana.
  • Blüm Santa Ana’s request for a Temporary Restraining Order argued that if New Patriot were allowed to terminate a parking agreement between the parties that Blüm Santa Ana’s business would be irreparably harmed and that Blüm Santa Ana was likely to prevail on its claim that New Patriot had breached the agreement by attempting to terminate Blüm Santa Ana’s right to access the parking.
  • The court found in Blüm Santa Ana’s favor that pending a hearing on a request for preliminary injunctive relief through JAMS, New Patriot, its officers, agents, servants, employees, and attorneys were directed to permit Blüm Santa Ana’s exclusive use and access to parking spaces.

Fidus Investment Corporation Announces Fourth Quarter And Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024
Janus, HVAC, DRIP, ZTR, Intelligence, Investment, Marketing, RCM, GMP, White label, Advertising, Fidus, Atmosphere of Earth, GAAP, Pest control, Software as a service, SBA, Heat, Research, Depreciation, Security (finance)

EVANSTON, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fidus Investment Corporation (NASDAQ:FDUS) (“Fidus” or the “Company”), a provider of customized debt and equity financing solutions, primarily to lower middle-market companies based in the United States, today announced its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Adjusted net investment income,(1) which excludes the capital gains incentive fee accrual, increased by $21.4 million, or 46.4%, to $67.5 million.
  • Our total portfolio investments at fair value were approximately 102.3% of the related cost basis as of December 31, 2023.
  • Management will host a conference call to discuss the operating and financial results at 9:00am ET on Friday, March 1, 2024.
  • Please ask to be joined into the Fidus Investment Corporation call.

Applied Therapeutics Announces $100 Million Private Placement

Retrieved on: 
Wednesday, February 28, 2024
Janus, Slate, RBC Capital Markets, Sale, Private, IPO, SVB Securities, Therapy, Private placement, Security (finance), UBS, Partnership

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it has entered into a securities purchase agreement for a private placement of $100 million of equity.

Key Points: 
  • The Private Placement is expected to result in gross proceeds to the Company of approximately $100 million, before deducting placement agent commissions and other offering expenses.
  • The Private Placement is expected to close on or about March 1, 2024, subject to the satisfaction of customary closing conditions.
  • Additional details regarding the Private Placement will be included in a Form 8-K to be filed by the Company with the Securities and Exchange Commission (“SEC”).
  • Leerink Partners, RBC Capital Markets, Baird, and UBS Investment Bank acted as placement agents in the transaction (the “Placement Agents”).

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement

Retrieved on: 
Wednesday, February 28, 2024
Janus, Therapy, SAN, Research, Sale, Richard Driehaus, SVB Securities, Paradigm

Crinetics anticipates the gross proceeds from the private placement to be approximately $350 million, before deducting any offering-related expenses.

Key Points: 
  • Crinetics anticipates the gross proceeds from the private placement to be approximately $350 million, before deducting any offering-related expenses.
  • The private placement is expected to close on or about March 1, 2024, subject to the satisfaction of customary closing conditions.
  • Leerink Partners, Piper Sandler, Baird, Citizens JMP, H.C. Wainwright & Co., and LifeSci Capital are acting as placement agents to the Company in connection with the private placement.
  • Crinetics has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in the private placement no later than the 40th day after the pricing of the private placement.

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024
Janus, Acquisition, Week, Psoriasis, GTN, Research, Health Canada, Investment, Inflammation, FDA, Marketing, Atopic dermatitis, Food, Dermatitis, Growth, Shanda, Patent, JAK1, PDUFA, Pharmacy benefit management, PDE4, Alopecia areata, Food and Drug Administration, Webcast, Half-life, Disease, SLR, Itch, NDA, Prescription, Scalp, Pharmaceutical industry

The Company saw significant GTN improvement in the fourth quarter compared to the GTN in the third quarter, and anticipates further GTN improvement in 2024.

Key Points: 
  • The Company saw significant GTN improvement in the fourth quarter compared to the GTN in the third quarter, and anticipates further GTN improvement in 2024.
  • Total revenues for the quarter ended December 31, 2023 were $13.5 million compared to $3.0 million for the corresponding period in 2022.
  • Net cash used in operating activities was $56.2 during the fourth quarter and $247.1 million during the full year 2023.
  • Arcutis management will host a conference call and webcast today at 8:30 am ET to discuss the financial results for the quarter and year and provide a business update.

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, February 22, 2024
Well, Janus, International, Neoplasm, Psoriasis, STAT6, Research, Toxicity, AML, Doctor of Philosophy, ASH, Investment, Blood, Atopic dermatitis, Cash, Growth, Janus kinase, Sale, Lupus, Skin, CTCL, PD-1, Inflammation, Society, JAK, Biomarker, Therapy, Immunology, Hidradenitis suppurativa, Administration, Webcast, Inflammatory bowel disease, Patient, Autoimmunity, Arm, Lymphoma, TYK2, Clinical trial, HS, TPD, G&A, Development, Dupilumab, Phase 1, Human, Pharmaceutical industry

Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.

Key Points: 
  • Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.
  • Enrollment in both trials is ongoing, with topline data expected to be reported in the first half of 2025.
  • Kymera unveiled its first-in-class oral STAT6 degrader, KT-621, at its Immunology R&D Day in January.
  • To access the conference call via phone, please dial +1 (833) 630-2127 or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call.

LEO Pharma Unveils Late-Breaking Data for Landmark DELTA 3 Open-Label Extension Trial at the 2024 AAD Annual Meeting

Retrieved on: 
Saturday, March 9, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Janus, Medicine, AAD, Safety, JAK, COVID-19, Abstract, Patient, CHE, Congress, Disease, LEO, Leo Pharma, American Academy, Pharmaceutical industry

For DELTA 3, subjects who completed the 16-week treatment period in one of the parent trials DELTA 1 and DELTA 2 were treated with twice daily delgocitinib cream as needed to control their chronic hand eczema for 36 weeks.

Key Points: 
  • For DELTA 3, subjects who completed the 16-week treatment period in one of the parent trials DELTA 1 and DELTA 2 were treated with twice daily delgocitinib cream as needed to control their chronic hand eczema for 36 weeks.
  • “Having the opportunity to present the DELTA 3 findings for the first time at AAD is a chance to prove our complete dedication to addressing the immense burden of this disease.
  • By continuing to share our key data at major dermatology congresses, we hope to drive forward the clinical development of delgocitinib cream as a potential new treatment option.”
    Key secondary endpoints demonstrated an efficacy profile consistent with DELTA 1 and 2 parent trials.
  • Alongside the presentation, new data sets at AAD were shared as e-posters from the preceding DELTA 1 and 2 trials regarding safety, efficacy and systemic exposure.2,3,4

Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement

Retrieved on: 
Thursday, March 7, 2024
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Janus, Attention, Prospectus, Medicine, Capital market, MindMed, Telephone, RBC Capital Markets, File, Cantor, Sale, Form, Richard Driehaus, State Street, SVB Securities, Security (finance)

In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares at a price of $6.00 per common share.

Key Points: 
  • In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares at a price of $6.00 per common share.
  • Gross proceeds to MindMed from the underwritten offering and concurrent private placement, before deducting underwriting commissions, placement agent fees and other offering-related expenses, are expected to be approximately $175 million.
  • Leerink Partners and Cantor are acting as joint bookrunning managers for the underwritten offering and placement agents for the private placement.
  • RBC Capital Markets is acting as lead manager for the underwritten offering and placement agent for the private placement.

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants

Retrieved on: 
Friday, March 1, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Genetics, Clinical Trials, Janus, Attention, Prospectus, Precision BioSciences, Gene editing, Telephone, Floor, Sale, Precision, Madison Avenue, Guggenheim Partners, Security (finance)

The warrants have an exercise price of $20.00 per share and are exercisable immediately and will expire five years following the date of issuance.

Key Points: 
  • The warrants have an exercise price of $20.00 per share and are exercisable immediately and will expire five years following the date of issuance.
  • The financing consisted of participation from leading life sciences investors, including Perceptive Advisors, Janus Henderson Investors, Aquilo Capital Management, LLC and LYFE Capital.
  • In addition, Precision BioSciences has granted the underwriter a 30-day option to purchase up to an additional 375,000 shares of its common stock and/or warrants to purchase up to 375,000 shares of common stock, at the combined public offering price and less underwriting discounts and commissions.
  • All shares of common stock and accompanying warrants to be sold in the offering will be sold by Precision.